{
    "root": "348b0d24-a89c-3f4e-e063-6394a90a183d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin and Clavulanate Potassium",
    "value": "20250507",
    "ingredients": [
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_487869"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        }
    ],
    "indications": {
        "text": "amoxicillin clavulanate potassium tablets indicated treatment infections adults pediatric patients , due susceptible isolates designated bacteria conditions listed : lower respiratory tract infections-caused beta\u2011lactamase\u2011producing isolates haemophilus influenzaeand moraxella catarrhalis . acute bacterial otitis media-caused beta\u2011lactamase\u2011producing isolates h. influenzaeand m. catarrhalis . sinusitis-caused beta\u2011lactamase\u2011producing isolates h. influenzaeand m. catarrhalis . skin skin structure infections-caused beta\u2011lactamase\u2011producing isolates staphylococcus aureus , escherichia coli , klebsiellaspecies . urinary tract infections-caused beta\u2011lactamase\u2011producing isolates e. coli , klebsiellaspecies , enterobacterspecies . limitations susceptibility test results show susceptibility amoxicillin , indicating beta-lactamase production , amoxicillin clavulanate potassium tablets used . usage reduce development drug\u2011resistant bacteria maintain effectiveness amoxicillin clavulanate potassium tablets antibacterial drugs , amoxicillin clavulanate potassium tablets used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "acute bacterial otitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_206994"
            }
        ]
    },
    "contraindications": {
        "text": "adults pediatric patients greater 40 kg : 875 mg every 12 hours , based amoxicillin component . ( 2.2 , 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "amoxicillin clavulanate potassium tablets usp , 875mg/125mg : scored off-white film coated capsule-shaped tablet , debossed ww949 upper side bisected side , contains 875 mg amoxicillin trihydrate 125 mg clavulanic acid potassium salt ( equivalent 149 mg clavulanate potassium ) . ndc : 70518-4148-00 ndc : 70518-4148-01 ndc : 70518-4148-02 ndc : 70518-4148-03 ndc : 70518-4148-04 packaging : 100 1 box packaging : 1 1 pouch packaging : 20 1 blister pack packaging : 30 1 blister pack packaging : 14 1 blister pack store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight container defined usp , child-resistant closure ( required ) . advise patients keep closed container . keep medications reach children . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium tablets beta-lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium tablets ( 4.2 )",
    "indications_original": "Amoxicillin and Clavulanate Potassium Tablets are indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:\n                  \n                     \n                        Lower Respiratory Tract Infections-caused by beta\u2011lactamase\u2011producing isolates of\n  \n   Haemophilus influenzaeand\n  \n   Moraxella catarrhalis.\n \n  \n                     \n                        Acute Bacterial Otitis Media-caused by beta\u2011lactamase\u2011producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Sinusitis-caused by beta\u2011lactamase\u2011producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Skin and Skin Structure Infections-caused by beta\u2011lactamase\u2011producing isolates of\n  \n   Staphylococcus aureus,\n  \n   Escherichia coli, and\n  \n   Klebsiellaspecies.\n \n  \n                     \n                        Urinary Tract Infections-caused by beta\u2011lactamase\u2011producing isolates of\n  \n   E. coli,\n  \n   Klebsiellaspecies, and\n  \n   Enterobacterspecies.\n \n  \n                  \n                  \n                     Limitations of Use\n                       When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium Tablets should not be used.\n\n \n                  \n                     Usage\n                       To reduce the development of drug\u2011resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium Tablets and other antibacterial drugs, Amoxicillin and Clavulanate Potassium Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "Adults and Pediatric Patients greater than 40 kg: 875 mg\u00a0every 12 hours, based on amoxicillin component. ( 2.2 , 2.3 )",
    "warningsAndPrecautions_original": "Amoxicillin and Clavulanate Potassium Tablets USP, 875mg/125mg: Each scored Off-white film coated capsule-shaped tablet, debossed with WW949 on the upper side and bisected on the other side, contains 875 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium).\n                  \n                  \n                  NDC: 70518-4148-00\n                  NDC: 70518-4148-01\n                  NDC: 70518-4148-02\n                  NDC: 70518-4148-03\n                  NDC: 70518-4148-04\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 20 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BLISTER PACK \n                  \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).\n                  Advise patients to keep in a closed container.\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to\u00a0Amoxicillin and Clavulanate Potassium\u00a0Tablets\u00a0or to other beta-lactams\u00a0(e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with\u00a0Amoxicillin and Clavulanate Potassium\u00a0Tablets ( 4.2 )",
    "drug": [
        {
            "name": "Amoxicillin and Clavulanate Potassium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        }
    ]
}